T
Thomas J. Prior
Researcher at Janssen Pharmaceutica
Publications - 12
Citations - 820
Thomas J. Prior is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Conjoint analysis & Internal medicine. The author has an hindex of 6, co-authored 9 publications receiving 545 citations. Previous affiliations of Thomas J. Prior include University of Pennsylvania & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force
A. Brett Hauber,Juan Marcos Gonzalez,Catharina G.M. Groothuis-Oudshoorn,Thomas J. Prior,Deborah A. Marshall,Charles E. Cunningham,Maarten Joost IJzerman,John F.P. Bridges +7 more
TL;DR: In this paper, the authors present the ESTIMATE checklist, which includes a list of questions to consider when justifying the choice of analysis method, describing the analysis, and interpreting the results.
Journal ArticleDOI
A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Ajai Chari,Jesus G. Berdeja,Albert Oriol,Niels W.C.J. van de Donk,Paula Rodriguez,Elham Askari,Maria-Victoria Mateos,Monique C. Minnema,Raluca Verona,Suzette Girgis,Thomas J. Prior,Brandi Hilder,Jeffery S. Russell,Jenna D. Goldberg,Amrita Krishnan +14 more
TL;DR: The safety of talquetamab is characterized and a recommended phase 2 dose (RP2D) is identified and two dose-limiting toxicities were observed: clinically asymptomatic grade 4 increased lipase in the setting of a pancreatic plasmacytoma and level of consciousness decreased.
Journal ArticleDOI
Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
Jesus G. Berdeja,Amrita Krishnan,Albert Oriol,Niels W.C.J. van de Donk,Paula Rodriguez-Otero,Elham Askari,Maria-Victoria Mateos,Monique C. Minnema,Luciano J. Costa,Raluca Verona,Suzette Girgis,Thomas J. Prior,Brandi Hilder,Jeffery S. Russell,Jenna D. Goldberg,Ajai Chari +15 more
TL;DR: New immunotherapy targets in MM are needed as patients (pts) continue to relapse, and Talquetamab (JNJ-64407564) and GPRC5D is expressed on malignant plasma cells in MM.
Journal ArticleDOI
A block slipping on a sphere with friction: Exact and perturbative solutions
Thomas J. Prior,Eugene J. Mele +1 more
TL;DR: In this article, the location of the release point of a particle that slides on the surface of a frictionless sphere when it is released from rest at the top is studied. And the authors generalize this problem to include the effects of sliding friction and solve it by a perturbation expansion in the coefficient of friction.
Journal ArticleDOI
A Comparison of Two Experimental Design Approaches in Applying Conjoint Analysis in Patient-Centered Outcomes Research
TL;DR: The results indicate that orthogonal and D-efficient experimental designs have produced results that are statistically equivalent, and several qualitative findings that speak to the potential differences in these results that may have been statistically identified in a larger sample are identified.